Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of 124I-AT-03 in Systemic Amyloidosis
NCT05201911Phase 1Completed
- Sponsor
- Attralus
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 124I-AT-03 in systemic amyloidosis, sponsored by Attralus. Primary endpoint: Tissue distribution of 124I-AT-03 in select organs at Day 4. Started Nov 2021; status: completed.
02
Drugs
124I-AT-03
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT05201911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201911.